Edap TMS SA reported unaudited consolidated financial results for the third quarter of 2025. HIFU revenue grew 49% year over year, driven by increased Focal One sales and higher U.S. procedure volumes. Focal One system placements rose 167% year over year, while U.S. Focal One HIFU procedures increased by 15%. For the nine months ended September 30, 2025, total revenue was €37.8 million ($39.4 million), compared to €34.3 million ($37.2 million) in the same period of 2024. Operating loss for the period was €16.7 million ($18.7 million), compared to €16.8 million ($18.2 million) in 2024. Net loss was €17.7 million ($19.8 million), or (€0.47) per share, compared to €17.1 million ($18.5 million), or (€0.46) per share, in 2024. As of September 30, 2025, cash and cash equivalents were €10.6 million ($12.4 million). The company reiterated its 2025 financial guidance, expecting core HIFU business revenue to grow 26% to 34% year over year, and non-core ESWL and Distribution business revenue to decline 25% to 30%.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Edap TMS SA published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001171843-25-007072), on November 06, 2025, and is solely responsible for the information contained therein.
Comments